论文部分内容阅读
目的:探讨初治的Ⅰ~Ⅲ期中度侵袭性非何杰金淋巴瘤有效的化疗方案。方法:选择Ⅰ~Ⅲ期中度侵袭性非何杰金淋巴瘤患者182例,随机等分为A、B2组。A组采用CHOP方案化疗8个周期,实际完成73例;B组前4个周期采用CHOP方案,后4个周期采用DICE方案化疗,实际完成69例。2组患者化疗结束后均根据具体情况给予放疗。比较2组完全缓解(CR)率及1a、2a、3a、4a总生存率。结果:A组化疗结束后CR率为57.5%,1a总生存率86.3%,2a总生存率61.0%,3a总生存率48.8%,4a总生存率31.0%。B组化疗结束后CR率为66.7%,1a总生存率87.0%,2a总生存率69.8%,3a总生存率64.3%,4a总生存率56.3%。2组比较,CR率及1a、2a、3a总生存率差异均无统计学意义(P均>0.05),4a总生存率差异有统计学意义(P<0.05)。结论:Ⅰ~Ⅲ期中度侵袭性非何杰金淋巴瘤患者采用CHOP方案4个周期、DICE方案4个周期序贯化疗较单用CHOP方案8个周期化疗的4a总生存率有明显提高。
Objective: To investigate the effective chemotherapy regimens of moderately aggressive non-Hodgkin lymphoma of stage Ⅰ ~ Ⅲ. Methods: A total of 182 patients with stage Ⅰ ~ Ⅲ moderately aggressive non-Hodgkin’s lymphoma were randomly divided into A and B2 groups. In group A, 8 cycles of CHOP chemotherapy were performed, 73 cases were actually completed; CHOP was used in the first 4 cycles of group B and DICE was used in the next 4 cycles, and 69 cases were actually completed. Patients in both groups were given radiotherapy according to the specific conditions after chemotherapy. The complete remission (CR) rate and the overall survival rates of 1a, 2a, 3a, 4a were compared between the two groups. Results: The CR rate of group A after chemotherapy was 57.5%, the overall survival rate of 1a was 86.3%, the total survival rate of 2a was 61.0%, the total survival rate of 3a was 48.8% and the overall survival rate of 4a was 31.0%. In group B, the CR rate was 66.7%, the overall survival rate of 1a was 87.0%, the overall survival rate of 2a was 69.8%, the overall survival rate of 3a was 64.3% and the overall survival rate of 4a was 56.3%. There was no significant difference in CR rate and the overall survival rates of 1a, 2a and 3a between the two groups (all P> 0.05). There was significant difference in the overall survival rate of 4a (P <0.05). CONCLUSIONS: Patients with stage Ⅰ-Ⅲ moderate-grade non-Hodgkin’s lymphoma treated with CHOP regimen for 4 cycles had a significantly higher overall survival rate of 4 cycles with DICE compared with 8 cycles of CHOP alone.